Neximmune announces melanoma research collaboration with nyu langone's perlmutter cancer center

Gaithersburg, md, march 14, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced a research and evaluation collaboration with the laura and isaac perlmutter cancer center, a national cancer institute designated comprehensive cancer center and part of nyu langone health. the collaboration is centered around neximmune's artificial antigen presenting cells' (aapcs) ability to expand neoantigen-specific cd8+ t cells in apheresis material provided by melanoma patients. dr. jeffrey s. weber, deputy director of the laura and isaac perlmutter cancer center will guide the research and evaluation.
NEXI Ratings Summary
NEXI Quant Ranking